These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 28206679)

  • 1. Technical Note: Determination of individual thyroid clearance effective half-life with a common handheld electronic dosimeter.
    Fürstner M; Hentschel M; Spanjol PM; Prenosil GA; Weidner S; Krause T; Klaeser B
    Med Phys; 2017 Apr; 44(4):1558-1562. PubMed ID: 28206679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single uptake measurement for absorbed dose planning for radioiodine treatment of hyperthyroidism.
    Jönsson H; Mattsson S
    Cancer Biother Radiopharm; 2003 Jun; 18(3):473-9. PubMed ID: 12954135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study.
    Brinks P; Van Gils K; Kranenborg E; Lavalaye J; Dieckens D; Habraken JBA
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):935-940. PubMed ID: 27988801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
    Eschner W; Kobe C; Schicha H
    Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percentage uptake of treatment activity of I-131 by thyroid.
    Jackson G
    J Nucl Med; 1979 Apr; 20(4):366. PubMed ID: 536818
    [No Abstract]   [Full Text] [Related]  

  • 6. Estimated dose rates to members of the public from external exposure to patients with 131I thyroid treatment.
    Dewji S; Bellamy M; Hertel N; Leggett R; Sherbini S; Saba M; Eckerman K
    Med Phys; 2015 Apr; 42(4):1851-7. PubMed ID: 25832075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
    Canzi C; Zito F; Voltini F; Reschini E; Gerundini P
    Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
    Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
    Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Two-step radioiodine therapy in benign thyroid diseases during a single hospital visit--observations on 100 patients].
    Khandani A; Schicha H
    Nuklearmedizin; 1999; 38(5):140-3. PubMed ID: 10488480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
    Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
    Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy].
    Moka D; Voth E; Schicha H
    Nuklearmedizin; 1997 Apr; 36(3):87-92. PubMed ID: 9162907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
    Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
    Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioactive iodine treatment for hyperthyroidism.
    Haugen B; Hennessey JV; Wartofsky L
    J Clin Endocrinol Metab; 2012 Apr; 97(4):29A-30A. PubMed ID: 22493315
    [No Abstract]   [Full Text] [Related]  

  • 15. Thyroid echogenicity: A clue to precise individual dosimetry in radioiodine therapy of hyperthyroidism.
    Marković V; Eterović D; Stipanović P; Punda A
    Med Hypotheses; 2011 Feb; 76(2):153-6. PubMed ID: 20889262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reduction of thyroid volume following radioiodine therapy for functional autonomy].
    Luster M; Jacob M; Thelen MH; Michalowski U; Deutsch U; Reiners C
    Nuklearmedizin; 1995 Apr; 34(2):57-60. PubMed ID: 7761274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The outcome of treatment with adjusted dose of 131I to thyroid weight for Graves' disease by estimation of effective half life using a single radioiodine uptake measurement].
    Gomi Y; Watanabe M; Yoshimura H; Ishikawa N; Momotani N; Ito K; Inoue T; Ito K; Suzuki S
    Kaku Igaku; 2000 Mar; 37(2):109-14. PubMed ID: 10783569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining thyroid (131)I effective half-life for the treatment planning of Graves' disease.
    Willegaignon J; Sapienza MT; Coura Filho GB; Traino AC; Buchpiguel CA
    Med Phys; 2013 Feb; 40(2):022502. PubMed ID: 23387769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine therapy and thyrostatic drugs and iodine.
    Moka D; Dietlein M; Schicha H
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S486-91. PubMed ID: 12192550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiological parameterization of thyroid radioiodine kinetics.
    Eterović D; Brdar D; Barić A; Sladić S; Omrčen T; Punda A
    Nucl Med Commun; 2018 Jul; 39(7):593-596. PubMed ID: 29683932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.